Literature DB >> 1419611

Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients.

O Stål1, J Carstensen, T Hatschek, B Nordenskjöld.   

Abstract

Tumours from 336 breast cancer patients under the age of 50 were analysed for hormone receptor content and by DNA flow cytometry. Sixty-six percent of the tumours were positive for estrogen receptors (ER), 60% were progesterone receptor (PR) positive and 42% showed DNA diploid profiles. DNA hypodiploid tumours were relatively frequent (7%), especially in patients aged 40 years or less (11%). S-phase fraction (SPF), with a mean of 10%, correlated significantly with receptor status, DNA ploidy, lymph node status, tumour size and age. With a median follow-up period of 34 months, the distant recurrence-free interval was independently predicted by lymph node status, tumour size, SPF and PR content. Amongst the 212 patients who had not received adjuvant systemic treatment, receptor status was, in addition to lymph node status and SPF, independently related to distant recurrence rate. A high SPF identified a subgroup with high recurrence rate, comprising approximately one third of the node-negative patients. Similarly, the one third of node-positive patients who had PR-positive tumours with a low S-phase fraction formed a subgroup with low recurrence rate. We conclude that hormone receptor assays and DNA flow cytometry should be useful tools in the management of breast cancer patients less than 50 years of age.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1419611      PMCID: PMC1977426          DOI: 10.1038/bjc.1992.342

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry.

Authors:  G M Clark; L G Dressler; M A Owens; G Pounds; T Oldaker; W L McGuire
Journal:  N Engl J Med       Date:  1989-03-09       Impact factor: 91.245

2.  Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel.

Authors:  O Wrange; B Nordenskjöld; J A Gustafsson
Journal:  Anal Biochem       Date:  1978-04       Impact factor: 3.365

3.  Nuclear DNA content in mammary carcinomas in women aged 35 or younger.

Authors:  A von Rosen; A Fallenius; B Sundelin; G Auer
Journal:  Am J Clin Oncol       Date:  1986-10       Impact factor: 2.339

4.  Steroid receptor levels in breast cancer. Relationships with age and menopausal status.

Authors:  N Wilking; L E Rutqvist; B Nordenskjöld; L Skoog
Journal:  Acta Oncol       Date:  1989       Impact factor: 4.089

5.  Immunological quantitation of nuclear receptors in human breast cancer: relation to cytosolic estrogen and progesterone receptors.

Authors:  S M Thorpe
Journal:  Cancer Res       Date:  1987-04-01       Impact factor: 12.701

6.  Estrogen receptor quantitation and staging as complementary prognostic indicators in breast cancer: a study of 583 patients.

Authors:  W Godolphin; J M Elwood; J J Spinelli
Journal:  Int J Cancer       Date:  1981-12       Impact factor: 7.396

7.  Indicators of prognosis in node-negative breast cancer.

Authors:  H Sigurdsson; B Baldetorp; A Borg; M Dalberg; M Fernö; D Killander; H Olsson
Journal:  N Engl J Med       Date:  1990-04-12       Impact factor: 91.245

8.  Cell kinetics as a prognostic indicator in node-negative breast cancer.

Authors:  R Silvestrini; M G Daidone; P Valagussa; G Di Fronzo; G Mezzanotte; G Bonadonna
Journal:  Eur J Cancer Clin Oncol       Date:  1989-08

9.  DNA ploidy and S-phase fraction in primary breast carcinomas in relation to prognostic factors and survival for premenopausal patients at high risk for recurrent disease.

Authors:  A E Lykkesfeldt; I Balslev; I J Christensen; J K Larsen; H Mølgaard; B B Rasmussen; S Thorpe; C Rose
Journal:  Acta Oncol       Date:  1988       Impact factor: 4.089

10.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.

Authors:  B Fisher; J Costantino; C Redmond; R Poisson; D Bowman; J Couture; N V Dimitrov; N Wolmark; D L Wickerham; E R Fisher
Journal:  N Engl J Med       Date:  1989-02-23       Impact factor: 91.245

View more
  3 in total

1.  Improved detection of DNA aneuploidy in primary breast cancer using quantitative DNA image analysis in combination with fluorescent in situ hybridization technique.

Authors:  B Verdoodt; P Castelain; C Bourgain; M Kirsch-Volders
Journal:  Histochem J       Date:  1995-01

2.  Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers.

Authors:  M F Pichon; P Broet; H Magdelenat; J C Delarue; F Spyratos; J P Basuyau; S Saez; A Rallet; P Courriere; R Millon; B Asselain
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

3.  S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer.

Authors:  O Stål; L Skoog; L E Rutqvist; J M Carstensen; S Wingren; S Sullivan; A C Andersson; M Dufmats; B Nordenskjöld
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.